Molecular structure of RGB-286638, CAS Number: 784210-88-4
RGB-286638 (CAS 784210-88-4)
Alternate Names:
N-[1,4-dihydro-3-[4-[[4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N′-4-morpholinyl-urea
CAS Number:
784210-88-4
Molecular Weight:
545.6
Molecular Formula:
C29H35N7O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
RGB-286638 (CAS 784210-88-4) References
- Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry. | de Bruijn, P., et al. 2009. J Pharm Biomed Anal. 50: 977-82. PMID: 19628352
- Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors. | van der Biessen, DA., et al. 2014. Clin Cancer Res. 20: 4776-83. PMID: 25024258
- Targeting cell cycle regulators in hematologic malignancies. | Aleem, E. and Arceci, RJ. 2015. Front Cell Dev Biol. 3: 16. PMID: 25914884
- Overview of CDK9 as a target in cancer research. | Morales, F. and Giordano, A. 2016. Cell Cycle. 15: 519-27. PMID: 26766294
- Data-driven prioritization and preclinical evaluation of therapeutic targets in glioblastoma. | Brahm, CG., et al. 2020. Neurooncol Adv. 2: vdaa151. PMID: 33392504
- CDK inhibitors in cancer therapy, an overview of recent development. | Zhang, M., et al. 2021. Am J Cancer Res. 11: 1913-1935. PMID: 34094661
- Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer. | Laha, D., et al. 2022. J Exp Clin Cancer Res. 41: 282. PMID: 36151566
- An Overview of CDK Enzyme Inhibitors in Cancer Therapy. | Mounika, P., et al. 2023. Curr Cancer Drug Targets. 23: 603-619. PMID: 36959160
- RGB 286638, a novel multi-targeted small molecule inhibitor, induces multiple myeloma (MM) cell death through abrogation of CDKDependent and independent survival mechanisms[J]. | Cirstea D, Hideshima T, Pozzi S,. 2008,. Blood,. 112(11):: 2759.
- Overcoming p53 Loss with a Multi-Targeted Small Molecule Inhibitor in Multiple Myeloma[J]. | Cirstea D, Hideshima T, Santo L,. 2009,. Blood,. 114(22):: 4915.
Inhibitor of:
Cdc2L5, Cdk3, Cdk8, CPAN, FAM127B, NIF3L1 BP1, p107, PCTAIRE-2, TFIIH p89, and TMEM194.Activator of:
Cdc28, Cdk9, and Clb2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
RGB-286638, 250 mg | sc-507523 | 250 mg | $285.00 |